A fast-growing body of research signals potential health benefits of GLP-1s, the class of diabetes and weight-loss drugs known by names like Ozempic, beyond what they were initially approved to treat.

Novo’s semaglutide, sold under the brand names Ozempic for diabetes and Wegovy for obesity, had been on the FDA’s drug shortage list for over two years. During that time, patients flocked to ...